According to a recent LinkedIn post from Acclaro Medical, the company is highlighting external clinical recognition for a paper on a 2910 nm fiber laser authored by dermatologist Eric F. Bernstein. The post notes that this paper, published in Lasers in Surgery and Medicine on behalf of the American Society for Laser Medicine & Surgery, is among the most viewed articles of 2024.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests that the publication, titled “The 2910 nm Fiber Laser Is Safe and Effective for Improving Acne Scarring,” underscores growing interest in 2910 nm cold fiber laser technology for skin resurfacing. It further associates this momentum with Acclaro Medical’s UltraClear-branded solutions and emphasizes the importance of clinical evidence in advancing aesthetics and “Total Skin Health™.”
For investors, this highlighted recognition may indicate strengthening clinical validation around the technology platform underpinning UltraClear, which could support physician adoption and pricing power over time. Increased scholarly visibility in a reputable medical journal may enhance the company’s credibility with clinicians and partners, potentially improving its competitive positioning in the medical aesthetics laser segment.
If this attention translates into broader clinical usage and positive real-world outcomes, Acclaro Medical could benefit from higher procedure volumes and device demand, although the post does not provide commercial data or timelines. Investors may still wish to monitor future disclosures on regulatory status, reimbursement dynamics, and revenue traction to assess how this clinical momentum might convert into measurable financial results.